Answers are grounded in this paper and cite their sources.
Pimozide demonstrates apoptosis in chronic lymphocytic leukemia, indicating a dual action approach to overcome venetoclax resistance.
Chronic lymphocytic leukemia (CLL) progression and therapeutic resistance are driven in large part by protective signals from the tumor microenvironment (TME), which includes T-cell-derived cytokines such as interleukin-4 (IL-4) that promote survival via STAT signaling and upregulation of anti-apoptotic proteins such as the BCL-2 family member MCL-1. Although the BCL-2 inhibitor venetoclax has demonstrated significant clinical efficacy, microenvironment-induced resistance, particularly by MCL-1 upregulation, remains a major limitation. Here, we identify the FDA-approved antipsychotic drug pimozide as a dual-function agent that induces lysosome membrane permeabilization (LMP), leading to apoptosis in CLL cells through increased reactive oxygen species production (ROS). In addition, pimozide inhibited STAT5 phosphorylation, reduced IL-4-induced MCL-1 expression and prevented IL-4/CD40L-mediated inhibition of apoptosis. Importantly, pimozide remains effective in inducing apoptosis in CLL cells from patients who have relapsed following therapy. Pimozide also synergizes with venetoclax to induce apoptosis in CLL cells even following IL-4/CD40L signaling. This suggests that dual targeting of lysosomal function and STAT signaling represents a promising therapeutic approach to improve venetoclax efficacy and overcome TME-mediated drug resistance in CLL.
No takes yet. Share an insight, caveat, or question.
Gibson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: